Loading video...

Video Failed to Load

Go Home

“peptides aren’t meant to be regulated” $hims giga bull case activated

alc2022's profile picture

Antonio Linares

144,870 subscribers

96,778 views • 5 months ago •via X (Twitter)

Health & WellnessNews & PoliticsFinance
LIVE

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

Muscles aren’t meant to be hidden. They’re meant to be displayed.
1:08

Muscles aren’t meant to be hidden. They’re meant to be displayed.

Will Ject

20,237 views • 7 months ago

🚨 THE PEPTIDES BULL CASE FOR $HIMS Jonah Lupton - Founder & CIO of FirstWave Capital We discuss how peptides fit into Jonah's thesis for Hims, Jonah's $30K/year peptide regimen, the possibility of Hims x Lilly, retatrutide, and why he thinks Hims could 10x over the next 10 years 02:34 - How Jonah got into peptides 03:39 - Current Hims position 05:04 - Original Hims thesis in the teens 09:12 - FDA peptide timeline & July meeting 15:03 - Peptides are "80% of the thesis" 18:37 - Jonah's personal peptide stack 26:00 - Spending $30K a year on peptides 28:47 - Black market and WhatsApp China 30:25 - Gray market and the COA problem 31:05 - Why Hims wins on legitimacy 32:36 - Best, not first 32:54 - Frustration with Hims transparency 35:28 - Speed vs the Apple approach 37:45 - Surviving the Novo scare 42:46 - Branded vs compounded future 44:41 - Why Lilly matters more than Novo 50:18 - Valuation and the 2035 model 57:04 - Wrap up and other peptide plays Not financial, legal, or medical advice
58:38

🚨 THE PEPTIDES BULL CASE FOR $HIMS Jonah Lupton - Founder & CIO of FirstWave Capital We discuss how peptides fit into Jonah's thesis for Hims, Jonah's $30K/year peptide regimen, the possibility of Hims x Lilly, retatrutide, and why he thinks Hims could 10x over the next 10 years 02:34 - How Jonah got into peptides 03:39 - Current Hims position 05:04 - Original Hims thesis in the teens 09:12 - FDA peptide timeline & July meeting 15:03 - Peptides are "80% of the thesis" 18:37 - Jonah's personal peptide stack 26:00 - Spending $30K a year on peptides 28:47 - Black market and WhatsApp China 30:25 - Gray market and the COA problem 31:05 - Why Hims wins on legitimacy 32:36 - Best, not first 32:54 - Frustration with Hims transparency 35:28 - Speed vs the Apple approach 37:45 - Surviving the Novo scare 42:46 - Branded vs compounded future 44:41 - Why Lilly matters more than Novo 50:18 - Valuation and the 2035 model 57:04 - Wrap up and other peptide plays Not financial, legal, or medical advice

Hims House

124,070 views • 5 months ago

$hims is back at pre lawsuit levels. the bear case has nothing left. $nvo is now a key partner. peptides are going mainstream, and $hims is the largest healthcare d2c platform on earth, the only one with a verticalised peptide supply chain. $hims here is $amd at $75 last year.
27:46

$hims is back at pre lawsuit levels. the bear case has nothing left. $nvo is now a key partner. peptides are going mainstream, and $hims is the largest healthcare d2c platform on earth, the only one with a verticalised peptide supply chain. $hims here is $amd at $75 last year.

Antonio Linares

64,503 views • 2 months ago

Some places aren’t meant to be explored
0:59

Some places aren’t meant to be explored

CHOVE

62,644 views • 3 months ago

Some things just aren’t meant to be recorded
0:25

Some things just aren’t meant to be recorded

non aesthetic things

13,579,245 views • 2 years ago

How about not smacking screens that aren’t meant to be smacked? (Note: None are meant to be smacked.)
0:35

How about not smacking screens that aren’t meant to be smacked? (Note: None are meant to be smacked.)

Vital Vegas

92,789 views • 2 years ago

Some games aren’t meant to be finished fast They’re meant to be shared hunts, late nights, and one more run
0:27

Some games aren’t meant to be finished fast They’re meant to be shared hunts, late nights, and one more run

the9bit

27,397 views • 9 months ago

It started with a simple case… but the deeper she looked, the more desire, secrets, and danger began to intertwine, and some truths aren’t meant to be uncovered.
1:30

It started with a simple case… but the deeper she looked, the more desire, secrets, and danger began to intertwine, and some truths aren’t meant to be uncovered.

Meelky Fbaby

74,786 views • 5 months ago

PEPTIDES MARKET SIZE "There were maybe $5 to $10 billion on gray market peptides spent in the United States in 2025. And that's going to grow this year." -Abud Bakri MD 🤯🤯🤯 $HIMS
1:11

PEPTIDES MARKET SIZE "There were maybe $5 to $10 billion on gray market peptides spent in the United States in 2025. And that's going to grow this year." -Abud Bakri MD 🤯🤯🤯 $HIMS

Hims House

18,487 views • 4 months ago

SOME PEOPLE SIMPLY AREN’T MEANT TO BE HUNTERS 😭😭😭
0:44

SOME PEOPLE SIMPLY AREN’T MEANT TO BE HUNTERS 😭😭😭

T

333,375 views • 3 months ago

Some places aren’t meant to be crossed… this is one of them.
1:22

Some places aren’t meant to be crossed… this is one of them.

Damexa

55,952 views • 5 months ago

🚨 $HIMS HOUSE - NEW EPISODE!! Sam Koppelman - Co-founder of Hunterbrook Why he believes Andrew Dudum "wiped the floor with Novo", the peptides opportunity, and Hunterbrook's current $HIMS position 👀. We've wanted to have Sam on the show for over a year now, so it was fun to finally chat. Thanks again Sam! 02:39 - Hims x Novo are back! 07:40 - Why Dudum "wiped the floor" with Novo 11:38 - The semaglutide pill controversy 13:48 - Branded vs compounded GLP-1s 16:32 - Eli Lilly next? 17:36 - FDA enforcement since Makary 21:31 - Why peptides could be HUGE 30:57 - Hims subscriber growth and outlook 33:18 - Ro vs Hims 35:45 - Hunterbrook's current Hims position Not financial, legal, or medical advice
37:26

🚨 $HIMS HOUSE - NEW EPISODE!! Sam Koppelman - Co-founder of Hunterbrook Why he believes Andrew Dudum "wiped the floor with Novo", the peptides opportunity, and Hunterbrook's current $HIMS position 👀. We've wanted to have Sam on the show for over a year now, so it was fun to finally chat. Thanks again Sam! 02:39 - Hims x Novo are back! 07:40 - Why Dudum "wiped the floor" with Novo 11:38 - The semaglutide pill controversy 13:48 - Branded vs compounded GLP-1s 16:32 - Eli Lilly next? 17:36 - FDA enforcement since Makary 21:31 - Why peptides could be HUGE 30:57 - Hims subscriber growth and outlook 33:18 - Ro vs Hims 35:45 - Hunterbrook's current Hims position Not financial, legal, or medical advice

Hims House

67,972 views • 6 months ago

Some Frequencies Aren’t Meant To Be Heard. They’re Meant To Be Felt. ⚡️ Once You Experience It, Sound Feels Different.✨ Feel The Shift 👇
0:35

Some Frequencies Aren’t Meant To Be Heard. They’re Meant To Be Felt. ⚡️ Once You Experience It, Sound Feels Different.✨ Feel The Shift 👇

vegastar

12,586 views • 1 month ago

Some contents should be regulated, in this case, hyu jamaa si anafaa kushikwa...
2:55

Some contents should be regulated, in this case, hyu jamaa si anafaa kushikwa...

KIJANA WA ATWORI 🔸

174,603 views • 1 month ago

Some songs aren’t released, because they were meant to be felt, not heard 🫠
1:47

Some songs aren’t released, because they were meant to be felt, not heard 🫠

SathishARR

43,939 views • 1 year ago

Some moments aren’t meant to be changed… no matter how powerful you become ⏳
1:30

Some moments aren’t meant to be changed… no matter how powerful you become ⏳

Sparkplug102👌

151,673 views • 5 months ago

$HIMS 🚨 THE FDA PEPTIDES VOTE IS DAYS AWAY Peptides insider Jesse Morse, M.D. expects approval We discuss the FDA briefing document recommending *against* the 7 peptides, what the odds of approval are for each of the peptides under review (including BPC-157) and why U.S.-made API could be a major advantage for $HIMS 01:37 - FDA briefing document 03:24 - Getting peptides back in front of the FDA 08:58 - Prescribing peptides back in 2017 12:42 - Peptides safety data 16:08 - BPC-157 deep-dive and odds for approval 22:56 - TB-500 deep-dive 26:15 - Approval odds for the other 5 peptides 31:02 - Peptide efficacy data 34:40 - FDA politics and final decisions 40:30 - Peptides market size 42:48 - Training the doctors 47:20 - Shipping hurdles and gray-market risk 53:25 - Why peptides could reshape healthcare Not financial, legal, or medical advice
1:01:13

$HIMS 🚨 THE FDA PEPTIDES VOTE IS DAYS AWAY Peptides insider Jesse Morse, M.D. expects approval We discuss the FDA briefing document recommending *against* the 7 peptides, what the odds of approval are for each of the peptides under review (including BPC-157) and why U.S.-made API could be a major advantage for $HIMS 01:37 - FDA briefing document 03:24 - Getting peptides back in front of the FDA 08:58 - Prescribing peptides back in 2017 12:42 - Peptides safety data 16:08 - BPC-157 deep-dive and odds for approval 22:56 - TB-500 deep-dive 26:15 - Approval odds for the other 5 peptides 31:02 - Peptide efficacy data 34:40 - FDA politics and final decisions 40:30 - Peptides market size 42:48 - Training the doctors 47:20 - Shipping hurdles and gray-market risk 53:25 - Why peptides could reshape healthcare Not financial, legal, or medical advice

Hims House

185,491 views • 2 months ago

Some things aren’t meant to be announced. They’re meant to be felt. ÉLÉAN — CLOSER TO YOU. Created using Wan 3.0 Alibaba Cloud + OpenArt #OpenArtAdAwards #AICommercial #Luxury #Perfume #CinematicAI #GenerativeAI #Advertising #Storytelling
0:30

Some things aren’t meant to be announced. They’re meant to be felt. ÉLÉAN — CLOSER TO YOU. Created using Wan 3.0 Alibaba Cloud + OpenArt #OpenArtAdAwards #AICommercial #Luxury #Perfume #CinematicAI #GenerativeAI #Advertising #Storytelling

AntonioAI

471,633 views • 6 days ago

🚨 NEEDHAM ANALYST RYAN MACDONALD: PEPTIDES COULD BE A $30+ BILLION MARKET AND $HIMS IS POSITIONED TO WIN A BIG SHARE This is most thorough deep-dive we've done on the business side of peptides: We discuss the latest peptide news, how the FDA / PCAC process actually works, the size of the peptide opportunity, $HIMS' potential share, the Novo partnership, branded vs compounded economics, short interest, competition, valuation, and more. 🔥 01:58 - FDA briefing document breakdown 04:15 - The timeline of peptide approval 09:50 - Category 1 vs 503A Bulks List 11:34 - When will telehealths start to sell peptides? 14:25 - Sizing the peptide market 19:31 - Hims’ peptide share 21:55 - Peptide pricing & margins 24:45 - Peptides likely a 2027 revenue story 29:58 - Hims-Novo deal check-in 32:11 - Branded vs compounded GLP-1s margins 35:27 - Pills vs injectables 40:43 - International 42:04 - Hims' moat 46:22 - 2030 targets and valuation models 50:32 - Shorts, insiders, and catalysts Not financial, medical, or legal advice
1:00:30

🚨 NEEDHAM ANALYST RYAN MACDONALD: PEPTIDES COULD BE A $30+ BILLION MARKET AND $HIMS IS POSITIONED TO WIN A BIG SHARE This is most thorough deep-dive we've done on the business side of peptides: We discuss the latest peptide news, how the FDA / PCAC process actually works, the size of the peptide opportunity, $HIMS' potential share, the Novo partnership, branded vs compounded economics, short interest, competition, valuation, and more. 🔥 01:58 - FDA briefing document breakdown 04:15 - The timeline of peptide approval 09:50 - Category 1 vs 503A Bulks List 11:34 - When will telehealths start to sell peptides? 14:25 - Sizing the peptide market 19:31 - Hims’ peptide share 21:55 - Peptide pricing & margins 24:45 - Peptides likely a 2027 revenue story 29:58 - Hims-Novo deal check-in 32:11 - Branded vs compounded GLP-1s margins 35:27 - Pills vs injectables 40:43 - International 42:04 - Hims' moat 46:22 - 2030 targets and valuation models 50:32 - Shorts, insiders, and catalysts Not financial, medical, or legal advice

Hims House

85,085 views • 3 months ago

Today, we announce our most long-awaited offering — Superpower Peptides. For too long, Americans seeking access to peptides have been left with two options: go without, or turn to unregulated sources that put their health at risk. That's beginning to change. And we've been building for this moment. Introducing Superpower Peptides: • Pure. Third-party tested • Rigorously sourced • Backed by science As the FDA moves to restore regulated access to 12 key peptides we'll be here, ready. Existing members get early access today. Others can reserve their username on our waitlist: 👉 superpower . com / peptides The peptide era begins
0:25

Today, we announce our most long-awaited offering — Superpower Peptides. For too long, Americans seeking access to peptides have been left with two options: go without, or turn to unregulated sources that put their health at risk. That's beginning to change. And we've been building for this moment. Introducing Superpower Peptides: • Pure. Third-party tested • Rigorously sourced • Backed by science As the FDA moves to restore regulated access to 12 key peptides we'll be here, ready. Existing members get early access today. Others can reserve their username on our waitlist: 👉 superpower . com / peptides The peptide era begins

Max Marchione

1,012,009 views • 5 months ago